Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R. Brahmer, John A. Thompson, Christina Lacchetti et al.|Journal of Clinical Oncology|2018Cited by 3.7k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trialCamilla Zimmermann, Christopher Lo, Nadia Swami et al.|The Lancet|2014Cited by 1.8k
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiLMartin Reck, Christian Manegold, Joachim von Pawel et al.|Journal of Clinical Oncology|2009Cited by 1.5k
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerChristian Rolfo, David R. Gandara, Charles Swanton et al.|Journal of Thoracic Oncology|2021Cited by 642
An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on AccessNatasha B. Leighl, Bishal Gyawali|American Society of Clinical Oncology Educational Book|2021Cited by 167